search
Back to results

Cognitive Remediation Therapy Within a Secure Forensic Setting

Primary Purpose

Schizophrenia, Schizoaffective Disorder, Cognitive Deficits

Status
Completed
Phase
Not Applicable
Locations
Ireland
Study Type
Interventional
Intervention
Cognitive Remediation Therapy
Treatment as usual
Sponsored by
Central Mental Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring Cognitive remediation therapy, Psychiatric rehabilitation, Forensic mental health, Forensic psychiatry, Clinical psychology, Randomized controlled trial, Principle driven intervention, Psychological Intervention, Cognitive enhancement

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A Structured Clinical Interview for Diagnostic and Statistical Manual IV (SCID) diagnosis of schizophrenia or schizoaffective disorder.

Exclusion Criteria:

  • Acutely psychotic, or judged too dangerous to participate in treatment, or being over 65 years of age.

Sites / Locations

  • Central Mental Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cognitive Remediation Therapy

Treatment as Usual

Arm Description

Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.

Usual care.

Outcomes

Primary Outcome Measures

The MATRICS Consensus Cognitive Battery (MCCB)
Consensus neuropsychological assessment battery for cognitive deficits in schizophrenia

Secondary Outcome Measures

Social and Occupational Functioning Assessment Scale (SOFAS)
100 item rating scale for measuring real world functioning independent of symptoms
Positive and Negative Syndrome Scale (negative and disorganized factors)
Rating scale for assessing psychiatric symptoms associated with schizophrenia
Clinical Assessment Interview for Negative Symptoms (CAINS)
Rating scale for assessing the negative symptoms of schizophrenia

Full Information

First Posted
February 4, 2015
Last Updated
July 24, 2017
Sponsor
Central Mental Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02360813
Brief Title
Cognitive Remediation Therapy Within a Secure Forensic Setting
Official Title
Randomised Controlled Trial to Evaluate the Efficacy of Cognitive Remediation Within a Secure Forensic Setting for Schizophrenia Spectrum Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
January 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Central Mental Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical trial tests the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy for patients diagnosed with schizophrenia or schizoaffective disorder within a forensic hospital. It is hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance, real world functioning, symptoms, violence risk and benefit more from additional psychosocial treatment programmes over time relative to patients receiving treatment as usual. Furthermore it is hypothesised that it will be feasible to carry out such a study and that patients will report high rates of satisfaction with cognitive remediation therapy. Finally it is hypothesised that differences on the effectiveness measures will be maintained at 6 month follow up after the end of treatment.
Detailed Description
This is a single centre randomised clinical trial to evaluate the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy within a secure forensic setting for patients diagnosed with schizophrenia or schizoaffective disorder. The feasibility of the intervention will be assessed using key indicators such as rate of enrolment, retention of patients in the trial, blinding effectiveness, and completion rate of the primary outcome measure. The effectiveness of the intervention will be assessed using the MATRICS consensus cognitive battery, symptoms (PANSS and CAINS) and real world functioning (SOFAS: Social and occupational functioning assessment scale). The effect of cognitive remediation on violence risk (HCR-20), programme completion and recovery (Dundrum 3 & 4) will also be examined, where programme completion is a measure of attainments from participating in additional psychosocial interventions and recovery is a measure of stability of mental state. Patient satisfaction with cognitive remediation therapy will be assessed using a consumer constructed interview developed by Rose et al (2008) and administered by a social worker not involved in the delivery of cognitive remediation. The trial will take place at the Republic of Ireland's Central Mental Hospital (CMH). The CMH is the only secure forensic psychiatric hospital for the Republic of Ireland, a population of 4.6 million. CMH provides specialised care for adults who have a mental disorder and are at risk of harming themselves or others. After a baseline assessment to ensure eligibility and to obtain consent, an estimated 60 patients will be randomised to receive fourteen weeks of cognitive remediation versus treatment as usual. Patients who receive treatment as usual will be offered cognitive remediation upon completion of the study. Patients allocated to cognitive remediation will receive three individual sessions of cognitive remediation a week and one group session, fifty-six sessions in total The focus of the group session is to normalise cognitive difficulties that patients may be experiencing, to receive support and to help generalise gains. The primary outcome measure the MATRICS composite score and secondary outcome measures to assess real world functioning, symptoms, violence risk, programme completion and recovery will be administered at baseline, the end of treatment and at six month follow up. Secondary measures will also include feasibility outcomes and patient satisfaction with cognitive remediation therapy. All evaluators of the effectiveness measures will be blind to participant treatment condition at the time of assessment. The cognitive remediation therapy is a principle driven intervention consisting of nine treatment principles: Principle 1 refers to relationship building, Principle 2 refers to collaborative goal setting, Principle 3 involves the session structure, Principle 4 concerns the content of the sessions, Principle 5, concerns the pacing of sessions, Principle 6 involves scaffolding and errorless learning, Principle 7 refers to meta-cognitive strategies, Principle 8 involves generalisation of gains, finally Principle 9 refers to managing ambivalence. The actual therapy will involve the use of a combination on pen, paper and computerised materials to stimulate patient's cognitive capacity and to provide them with the opportunity to apply meta-cognitive strategies. The investigators hypothesise that it is feasible to carry out a randomised controlled trial within a single centre forensic setting and that patients will report high rates of satisfaction with cognitive remediation. It is also hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance (the primary outcome measure), real world functioning, symptoms and violence risk over time relative to patients receiving treatment as usual; specifically that there will be a treatment by time interaction. Furthermore it is hypothesised that these differences will be maintained at six month follow up after the end of treatment. In addition it is hypothesised that patients receiving cognitive remediation will show an improvement over time on the Dundrum programme completion and recovery scales compared to those receiving treatment as usual. While meta-analytic reviews have demonstrated that cognitive remediation therapy has a beneficial effect on the cognitive deficits experienced by patients with schizophrenia (Wykes et al 2011), to the best of our knowledge there has been no study with forensic mental health patients. The current study will help answer whether it is feasible to deliver cognitive remediation within a forensic mental health setting and whether it is acceptable to patients. The study aims to contribute to the evidence base for psychological interventions within a forensic setting and to answer the question as to whether cognitive remediation has a beneficial effect and if it does whether this effect is maintained over time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Schizoaffective Disorder, Cognitive Deficits
Keywords
Cognitive remediation therapy, Psychiatric rehabilitation, Forensic mental health, Forensic psychiatry, Clinical psychology, Randomized controlled trial, Principle driven intervention, Psychological Intervention, Cognitive enhancement

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
65 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cognitive Remediation Therapy
Arm Type
Experimental
Arm Description
Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
Arm Title
Treatment as Usual
Arm Type
Active Comparator
Arm Description
Usual care.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Remediation Therapy
Other Intervention Name(s)
Cognitive training, Cognitive rehabilitation, Cognitive enhancement
Intervention Description
Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
Intervention Type
Other
Intervention Name(s)
Treatment as usual
Other Intervention Name(s)
Standard care
Intervention Description
Keep getting usual care.
Primary Outcome Measure Information:
Title
The MATRICS Consensus Cognitive Battery (MCCB)
Description
Consensus neuropsychological assessment battery for cognitive deficits in schizophrenia
Time Frame
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Secondary Outcome Measure Information:
Title
Social and Occupational Functioning Assessment Scale (SOFAS)
Description
100 item rating scale for measuring real world functioning independent of symptoms
Time Frame
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Title
Positive and Negative Syndrome Scale (negative and disorganized factors)
Description
Rating scale for assessing psychiatric symptoms associated with schizophrenia
Time Frame
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Title
Clinical Assessment Interview for Negative Symptoms (CAINS)
Description
Rating scale for assessing the negative symptoms of schizophrenia
Time Frame
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Other Pre-specified Outcome Measures:
Title
Historical Clinical and Risk Management -20 (HCR-20)
Description
Rating scale for assessing violence risk
Time Frame
Group by time interaction: changes from baseline, to 12 months
Title
Dundrum Toolkit: Programme Completion and Recovery Scales
Description
Rating scale for assessing progress and recovery within a forensic mental health setting
Time Frame
Group by time interaction: changes from baseline to 12 months
Title
Patient satisfaction.
Description
Consumer developed interview exploring patient satisfaction with cognitive remediation.
Time Frame
Average 5 months.
Title
Feasibility outcome: rate of enrolment.
Description
Willingness of forensic mental health patients to participate in study.
Time Frame
12 months.
Title
Feasibility outcome: rate of retention.
Description
Number of patients who complete the intervention.
Time Frame
12 months.
Title
Feasibility outcome: blinding.
Description
Number of patients in which the blind is broken compared to number of patients in the study.
Time Frame
12 months.
Title
Completion rate of primary outcome measures
Description
Number of successfully completed primary outcome measures.
Time Frame
12 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A Structured Clinical Interview for Diagnostic and Statistical Manual IV (SCID) diagnosis of schizophrenia or schizoaffective disorder. Exclusion Criteria: Acutely psychotic, or judged too dangerous to participate in treatment, or being over 65 years of age.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Professor Harry G Kennedy, M.D.
Organizational Affiliation
Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Professor Gary Donohoe, Ph.D.
Organizational Affiliation
Department of Psychiatry, Trinity College Dublin.
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Dr. Ken W O'Reilly, D.Psych.Sc.
Organizational Affiliation
Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Central Mental Hospital
City
Dublin
ZIP/Postal Code
D 14
Country
Ireland

12. IPD Sharing Statement

Citations:
PubMed Identifier
18172019
Citation
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.
Results Reference
background
Citation
Rybarczyk B. (2011). Social and Occupational Functioning Assessment Scale (SOFAS). Encyclopedia of Clinical Neuropsychology. p 2313
Results Reference
background
PubMed Identifier
3616518
Citation
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
Results Reference
background
PubMed Identifier
23377637
Citation
Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry. 2013 Feb;170(2):165-72. doi: 10.1176/appi.ajp.2012.12010109.
Results Reference
background
Citation
Webster CD, Douglas KS, Eaves D, Hart SD. HCR-20: assessing risk for violence. Burnaby: Mental Health Law and Policy Institute, Simon Fraser University; 1997.
Results Reference
background
PubMed Identifier
23837697
Citation
Davoren M, Abidin Z, Naughton L, Gibbons O, Nulty A, Wright B, Kennedy HG. Prospective study of factors influencing conditional discharge from a forensic hospital: the DUNDRUM-3 programme completion and DUNDRUM-4 recovery structured professional judgement instruments and risk. BMC Psychiatry. 2013 Jul 9;13:185. doi: 10.1186/1471-244X-13-185.
Results Reference
background
Citation
Rose D, Wykes T, Farrier D, Doran AM, Sporel T & Bogner D (2008) What Do Clients Think of Cognitive Remediation Therapy?: A Consumer-Led Investigation of Satisfaction and Side Effects, American Journal of Psychiatric Rehabilitation. Rehabilitation, 11:2, 181-204.
Results Reference
background
PubMed Identifier
21406461
Citation
Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011 May;168(5):472-85. doi: 10.1176/appi.ajp.2010.10060855. Epub 2011 Mar 15.
Results Reference
background
PubMed Identifier
30646884
Citation
O'Reilly K, Donohoe G, O'Sullivan D, Coyle C, Corvin A, O'Flynn P, O'Donnell M, Galligan T, O'Connell P, Kennedy HG. A randomized controlled trial of cognitive remediation for a national cohort of forensic patients with schizophrenia or schizoaffective disorder. BMC Psychiatry. 2019 Jan 15;19(1):27. doi: 10.1186/s12888-019-2018-6.
Results Reference
derived
PubMed Identifier
26759167
Citation
O'Reilly K, Donohoe G, O'Sullivan D, Coyle C, Mullaney R, O'Connell P, Maddock C, Nulty A, O'Flynn P, O'Connell C, Kennedy HG. Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder. BMC Psychiatry. 2016 Jan 13;16:5. doi: 10.1186/s12888-016-0707-y.
Results Reference
derived

Learn more about this trial

Cognitive Remediation Therapy Within a Secure Forensic Setting

We'll reach out to this number within 24 hrs